Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Mega JL, et al. Among authors: scirica bm. JAMA. 2011 Nov 23;306(20):2221-8. doi: 10.1001/jama.2011.1703. Epub 2011 Nov 16. JAMA. 2011. PMID: 22088980 Clinical Trial.
The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study.
Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. Scirica BM, et al. J Am Coll Cardiol. 2006 Jul 4;48(1):37-42. doi: 10.1016/j.jacc.2006.02.052. Epub 2006 Jun 12. J Am Coll Cardiol. 2006. PMID: 16814646 Free article. Clinical Trial.
Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial).
Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Bonaca MP, et al. Among authors: scirica bm. Am J Cardiol. 2007 Feb 1;99(3):344-8. doi: 10.1016/j.amjcard.2006.08.035. Epub 2006 Nov 30. Am J Cardiol. 2007. PMID: 17261395 Clinical Trial.
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Trial Investigators. Morrow DA, et al. Among authors: scirica bm. JAMA. 2007 Apr 25;297(16):1775-83. doi: 10.1001/jama.297.16.1775. JAMA. 2007. PMID: 17456819 Clinical Trial.
A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.
Scirica BM, Morrow DA, Sadowski Z, Ruda M, Nicolau JC, Giugliano RP, Wiviott SD, Sabatine MS, Shui A, Antman EM, Braunwald E. Scirica BM, et al. Eur Heart J. 2007 Sep;28(17):2070-6. doi: 10.1093/eurheartj/ehm210. Epub 2007 Jun 28. Eur Heart J. 2007. PMID: 17600039 Clinical Trial.
269 results